GoodRx - Public Comps and Valuation Multiples

GoodRx Overview

About GoodRx

GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.

Founded

2015

HQ

Employees

738

Website

goodrx.com

Sectors

Health Benefits & Financial Solutions
Telemedicine & Virtual Care
Pharmacies
Vertical E-commerce
Consumer E-commerce
Price Comparison
HealthTech
FinTech

Financials

LTM Revenue $801M

LTM EBITDA $266M

EV

$1.8B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

GoodRx Financials

GoodRx has a last 12-month revenue of $801M and a last 12-month EBITDA of $266M.

In the most recent fiscal year, GoodRx achieved revenue of $792M and an EBITDA of $154M.

GoodRx expects next 12-month revenue of XXX and NTM EBITDA of XXX

See GoodRx valuation multiples based on analyst estimates

GoodRx P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$750M	$792M	XXX	XXX	XXX
Gross Profit	$701M	$683M	XXX	XXX	XXX
Gross Margin	93%	86%	XXX	XXX	XXX
EBITDA	$109M	$154M	XXX	XXX	XXX
EBITDA Margin	15%	19%	XXX	XXX	XXX
Net Profit	-$32.8M	-$8.9M	XXX	XXX	XXX
Net Margin	-4%	-1%	XXX	XXX	XXX
Net Debt	n/a	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

GoodRx Stock Performance

As of April 15, 2025, GoodRx's stock price is $4.

GoodRx has current market cap of $1.7B, and EV of $1.8B.

See GoodRx trading valuation data

GoodRx Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.8B	$1.7B	XXX	XXX	XXX	XXX	$0.35

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

GoodRx Valuation Multiples

As of April 15, 2025, GoodRx has market cap of $1.7B and EV of $1.8B.

GoodRx's trades at 2.3x LTM EV/Revenue multiple, and 6.8x LTM EBITDA.

Analysts estimate GoodRx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for GoodRx and 10K+ public comps

GoodRx Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$1.8B	XXX	XXX	XXX
EV/Revenue	2.3x	XXX	XXX	XXX
EV/EBITDA	11.8x	XXX	XXX	XXX
P/E	105.1x	XXX	XXX	XXX
P/E/Growth	0.8x	XXX	XXX	XXX
EV/FCF	16.0x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get GoodRx Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

GoodRx Valuation Multiples

GoodRx's NTM/LTM revenue growth is 5%

GoodRx's revenue per employee for the last fiscal year averaged $1.1M, while opex per employee averaged $0.9M for the same period.

Over next 12 months, GoodRx's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate GoodRx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for GoodRx and other 10K+ public comps

GoodRx Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	6%	XXX	XXX	XXX	XXX
EBITDA Margin	19%	XXX	XXX	XXX	XXX
EBITDA Growth	41%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	24%	XXX	XXX	XXX	XXX
Revenue per Employee	$1.1M	XXX	XXX	XXX	XXX
Opex per Employee	$0.9M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	46%	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	15%	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	16%	XXX	XXX	XXX	XXX
Opex to Revenue	86%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry